Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
April 24, 2024

OSR Holdings, SillaJen sign MoU to pursue drug development

Global healthcare holding company OSR Holdings has entered into a memorandum of understanding (MoU) with SillaJen, a South Korea-based biotechnology company with a pipeline of immuno-oncology drug candidates.

The companies will leverage shared technology as well as clinical development resources to create synergies in therapeutics development. Credit: Louis Reed/Unsplash.